Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Undiagnosed Diseases Network, |
RCV000505816 | SCV000746659 | likely pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | 2017-12-14 | criteria provided, single submitter | clinical testing | The c.971C>T (p.Thr324Ile) variant in MSTO1 is a nonsense variant. This variant was identified as a compound heterozygote with c.676C>T (p.Gln226Ter). The variant is seen in 13 individual in gnomAD as a heterozygote and has been reported in a similarly affected patient. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000505816 | SCV001623323 | likely pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | 2021-04-23 | criteria provided, single submitter | clinical testing | Variant summary: MSTO1 c.971C>T (p.Thr324Ile) results in a non-conservative amino acid change located in the DML1/Misato, tubulin domain of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 250888 control chromosomes (gnomAD). c.971C>T has been reported in the literature in four independent indviduals carrying a second MSTO1 variant, whose clinical features overlap with Mitochondrial Myopathy-Cerebellar Ataxia-Pigmentary Retinopathy Syndrome, including delayed motor and speech development, muscle weakness, unsteady gait/poor coordination, tremor, and abnormal EMG, MRI and/or muscle biopsy (Nasca_2017, Donkervoort_2019, Jiao_2020, Lee_2020). To our knowledge, no conclusive functional/experimental studies have been performed on the variant of interest. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely pathogenic, and one laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Gene |
RCV001788237 | SCV002030986 | likely pathogenic | not provided | 2024-06-03 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29339779, 28544275, 31130378, 30684668, 31607746, 31463572, 35598585, 33222031, 35446979, 33672784, 36468072) |
3billion | RCV000505816 | SCV002059089 | pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | 2022-01-03 | criteria provided, single submitter | clinical testing | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000438833, PS1_S). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:28544275, PS3_S). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000043, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. |
Kasturba Medical College, |
RCV000505816 | SCV002499642 | likely pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | criteria provided, single submitter | clinical testing | ||
Juno Genomics, |
RCV000505816 | SCV005416914 | likely pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | criteria provided, single submitter | clinical testing | PM2_Supporting+PS3_Supporting+PM3_Strong+PP4 | |
OMIM | RCV000505816 | SCV000600007 | pathogenic | Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome | 2017-09-22 | no assertion criteria provided | literature only | |
Ambry Genetics | RCV001266925 | SCV001445106 | uncertain significance | Inborn genetic diseases | 2017-12-18 | flagged submission | clinical testing |